Results 101 to 110 of about 23,896 (206)

COVID-19, Eosinophils, and Biologicals for Severe Asthma

Frontiers in Allergy, 2022
Lombardi, Carlo, Bagnasco, Diego, Passalacqua, Giovanni   +2 more
openaire   +3 more sources

Mepolizumab treatment alters the functional phenotype of eosinophils in severe eosinophilic asthma. [PDF]

Front Immunol
Miguéns-Suárez P, Martelo-Vidal L, Vázquez-Mera S, Blanco-Aparicio M, Calvo-Álvarez U, González-Fernández C, Mosteiro-Añón M, Corbacho-Abelaira D, Hermida-Valverde T, Calvo-Henríquez C, Nieto-Fontarigo JJ, Salgado FJ, González-Barcala FJ.   +12 more
europepmc   +1 more source

Characteristics of Patients with Severe Uncontrolled Asthma in Saudi Arabia: A Cross-Sectional Study

Journal of Asthma and Allergy
Riyad O Al-Lehebi,1,2 Rana A Saleh,3 Abdalla M Alasiri,4 Bader J Alghamdi,5,6 Hajer Y Almudaiheem,7,8 Ahmed H Al-jedai,8,9 Eid A Almutairi,3 Haifa Aldakhil,10 Khaulah A Alokili,7 Fahad Zuriqan,7 Adeeb A Bulkhi11 1Pulmonary Department, King Fahad Medical ...
Al-Lehebi RO, Saleh RA, Alasiri AM, Alghamdi BJ, Almudaiheem HY, Al-jedai AH, Almutairi EA, Aldakhil H, Alokili KA, Zuriqan F, Bulkhi AA   +10 more
doaj  

Functional respiratory imaging reveals early structural and functional airway responses to benralizumab in severe eosinophilic asthma. [PDF]

BMJ Open Respir Res
Conemans L, Deng Q, Simons SO, Franssen FME, Spruit MA, Hajian B.   +5 more
europepmc   +1 more source

Identification of key genes predicting the efficacy of mepolizumab in the treatment of severe eosinophilic asthma. [PDF]

Sci Rep
Xinmin P, Jinxia C, Fengyuan L.
europepmc   +1 more source

<p>Onset of Effect, Changes in Airflow Obstruction and Lung Volume, and Health-Related Quality of Life Improvements with Benralizumab for Patients with Severe Eosinophilic Asthma: Phase IIIb Randomized, Controlled Trial (SOLANA) [Corrigendum]</p>

, 2020
Reynold A. Panettieri, Tobias Welte, Kartik Shenoy, Stephanie Korn, Margret Jandl, Edward Kerwin, Rosa Feijoo, Peter B. Barker, Richard F. Olsson, Ubaldo J. Martin   +9 more
openalex   +2 more sources

Clinical remission in patients with severe eosinophilic asthma treated with benralizumab over 24 months: Post hoc analysis of the ANANKE study. [PDF]

World Allergy Organ J
Canonica GW, Senna G, Brussino L, Aliani M, Altieri E, Bracciale P, Caiaffa MF, Cameli P, Caminati M, Caruso C, Centanni S, De Michele F, Del Giacco S, Di Marco F, Malerba L, Menzella F, Rogliani P, Romagnoli M, Schino P, Schroeder JW, Vultaggio A, D'Amato M, Pelaia G.   +22 more
europepmc   +1 more source

Anti-IL-5 Biologicals Targeting Severe Late Onset Eosinophilic Asthma

, 2019
Leyla Pur Özyiğit, Ayşe Bilge Öztürk, Sevim Bavbek   +2 more
openalex   +2 more sources

Targeting Eosinophils in Asthmatic Inflammation: Benefits and Drawbacks

Journal of Inflammation Research
David Broide Department of Medicine, University of California San Diego, La Jolla, CA, 92093-0635, USACorrespondence: David Broide, Department of Medicine, University of California San Diego, La Jolla, CA, 92093-0635, USA, Email dbroide@health.ucsd ...
Broide D
doaj  

Persistent airway obstruction in severe eosinophilic asthma: targeting interleukin-5 and eosinophils. [PDF]

Eur Respir Rev
Hanania NA, Herth FJF.
europepmc   +1 more source